Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: How ultrasound changed the practice of rheumatology: echoes of a 30-year collaboration.

Zeitschrift fur Rheumatologie·2026
Same author

Secukinumab for Giant Cell Arteritis.

NEJM evidence·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data.

Therapeutic advances in musculoskeletal disease·2026
Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026
Same author

Treatment of giant cell arteritis: focus on upadacitinib.

Expert opinion on pharmacotherapy·2026
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

58

[Polymyalgia rheumatica: What's new?]

Wolfgang A Schmidt1

  • 1Klinik für Innere Medizin, Rheumatologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin-Buch, Deutschland.

Deutsche Medizinische Wochenschrift (1946)
|August 15, 2024
PubMed
Summary
This summary is machine-generated.

Specialist diagnosis improves polymyalgia rheumatica (PMR) care, reducing misdiagnosis and hospitalizations. Advanced imaging and new treatments like Sarilumab offer better management for PMR and related giant cell arteritis (GCA).

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

97
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.1K

Related Experiment Videos

Last Updated: Jun 16, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

58
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

97
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.1K

Area of Science:

  • Rheumatology
  • Medical Imaging
  • Pharmacology

Context:

  • Polymyalgia rheumatica (PMR) diagnosis is often delayed, with only 25% of patients seeing specialists.
  • Expert recommendations emphasize specialist confirmation to prevent misdiagnosis and reduce glucocorticoid dependency.
  • PMR shares inflammatory characteristics with giant cell arteritis (GCA), necessitating careful diagnostic evaluation.

Purpose:

  • To highlight the importance of specialist diagnosis in polymyalgia rheumatica (PMR).
  • To discuss the role of imaging modalities like ultrasound in diagnosing PMR and detecting co-existing giant cell arteritis (GCA).
  • To review current and emerging therapeutic strategies for PMR management.

Summary:

  • Specialist care improves PMR diagnosis, potentially lowering glucocorticoid doses and hospitalizations.
  • Imaging techniques, particularly ultrasound, are crucial for identifying characteristic inflammatory changes and detecting subclinical GCA in PMR patients.
  • While glucocorticoids remain primary, targeted therapies like Sarilumab and Tocilizumab show promise for recurrent or refractory PMR.

Impact:

  • Enhanced diagnostic accuracy for PMR, leading to more appropriate and timely treatment.
  • Improved patient outcomes through reduced misdiagnosis, optimized glucocorticoid use, and effective targeted therapies.
  • Recognition of the GCA-PMR spectrum disease fosters a more integrated approach to managing these related inflammatory conditions.